Abbvie Company Profile

What is the competitive landscape for ABBVIE

ABBVIE has one hundred and forty-three approved drugs.

There are two hundred and thirty-two US patents protecting ABBVIE drugs.

There are two thousand nine hundred and forty-five patent family members on ABBVIE drugs in seventy-three countries and four hundred and twenty-seven supplementary protection certificates in nineteen countries.

Summary for Abbvie

International Patents:	2945
US Patents:	232
Tradenames:	129
Ingredients:	103
NDAs:	143
Drug Master File Entries:	1
Patent Litigation for Abbvie:	See patent lawsuits for Abbvie

Drugs and US Patents for Abbvie

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	CARTROL	carteolol hydrochloride	TABLET;ORAL	019204-002	Dec 28, 1988		DISCN	No	No
Abbvie	HARMONYL	deserpidine	TABLET;ORAL	010796-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-007	Aug 15, 2011		RX	Yes	Yes
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-001	Dec 23, 2014	AB	RX	Yes	No	8,168,209*PED				Y

Expired US Patents for Abbvie

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020708-001	Mar 7, 1997	4,728,721
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-008	Aug 15, 2011	5,643,607
Abbvie	NIASPAN TITRATION STARTER PACK	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-005	Jul 28, 1997	6,406,715
Abbvie	TRICOR	fenofibrate	TABLET;ORAL	021656-001	Nov 5, 2004	7,041,319

Paragraph IV (Patent) Challenges for ABBVIE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Gel	10%		2014-06-19
	Tablets	48 mg		2008-07-01
	Injection	10 mg/mL (2 mL)		2018-07-13
	Extended-release Capsules	7 mg, 14 mg, 21 mg		2013-06-17
	Injection	2 mg/mL, 10 mL vial		2009-08-12
	Tablets	2.5 mg/200 mg		2006-02-24
	Delayed-release Tablets	800 mg		2011-07-13
	Capsules	14 mg/10 mg and 28 mg/10 mg		2015-05-18
	Tablets	10 mg, 20 mg, and 40 mg		2015-01-21
	Ophthalmic Solution	0.40%		2005-01-28
	Extended-release Tablets	250 mg		2004-05-03
	Capsules	7 mg/10 mg		2016-09-26
	Opthalmic Solution	0.45%		2011-08-24
	Oral Solution	80 mg/20 mg per mL		2014-06-19
	Extended-release Tablets	7.5 mg and 15 mg		2008-12-22
	Ophthalmic Solution	0.15%		2006-11-03
	Tablets	100 mg		2010-12-21
	Extended-release Tablets	1 mg/240 mg		2008-02-20
	Ophthalmic Solution	0.25%		2014-07-30
	Capsules	4 mg and 8 mg		2012-10-09
	Tablets	5 mg/80 mg		2017-06-09
	Ophthalmic Solution	0.01%		2011-04-05
	Delayed-release Capsules	45 mg		2009-09-02
	Capsules	1 mcg and 2 mcg		2008-10-14
	Tablets	5 mg and 10 mg		2007-10-16
	Topical Solution	0.03%		2010-05-03
	Extended-release Capsules	20 mg, 40 mg, 80 mg and 120 mg		2017-07-25
	Gel	7.5%		2017-02-13
	Tablets	400 mg and 600 mg		2010-05-10
	Capsules	10 mg and 20 mg		2005-03-30
	Extended-release Capsules	28 mg		2013-06-12
	Injection	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial		2009-08-04
	Tablets	145 mg		2007-10-19
	Suppository	1000 mg		2013-05-24
	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg		2013-06-10
	Injection	400 mg/vial and 600 mg/vial		2014-10-29
	Tablets	5 mg/200 mg		2005-05-27
	Extended-release Tablet	500 mg		2010-12-06
	Capsules	21 mg/10 mg		2016-09-23
	Opthalmic Solution	0.45%		2011-08-23
	Tablets	100 mg/25 mg		2008-12-23
	Extended-release Tablets	500 mg		2005-02-08
	Ophthalmic Solution	0.10%		2006-12-20
	Capsules	145 mcg and 290 mcg		2016-08-30
	Extended-release Tablets	2 mg/180 mg and 2 mg/240 mg		2007-11-09
	Ophthalmic Solution	0.2%/0.5%		2008-11-21
	Capsules	100 mg		2012-10-31
	Extended-release Tablets	4 mg/ 240 mg		2007-07-24
	Ophthalmic Solution	0.03%		2008-12-22
	Delayed-release Capsules	400 mg		2014-06-17
	Injection	0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials		2008-11-28
	Tablets	1 mg, 2 mg and 4 mg		2004-10-04
	Ophthalmic Solution	0.5%		2010-12-07
	Delayed-release Capsules	135 mg		2009-09-01
	Capsules	4 mcg		2008-08-25
	Tablets	12.5 mg, 25 mg, 50 mg, and 100 mg		2013-01-14
	Capsules	5 mg		2005-08-17
	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg		2013-08-16

International Patents for Abbvie Drugs

Country	Patent Number	Estimated Expiration
Chile	2014000059
Japan	2016147878
World Intellectual Property Organization (WIPO)	2016065019
World Intellectual Property Organization (WIPO)	2007103960

Supplementary Protection Certificates for Abbvie Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1441735	08C0026	France		PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
2340029	1590012-9	Sweden		PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119
1663996	2017/050	Ireland		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/17/1209 20170713
2246360	23/2013	Austria		PRODUCT NAME: LINACLOTID UND PHARMAZEUTISCH ANNEHMBARE SALZE HIERVON; REGISTRATION NO/DATE: EU/1/12/801/001-004 (MITTEILUNG) 20121128

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Abbvie
• Abbvie Endocrine
• Abbvie Endocrine Inc

Pharmaceutical Competitive Landscape Analysis: AbbVie's Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, AbbVie has emerged as a formidable player, carving out a significant market position through innovation, strategic acquisitions, and a robust product portfolio. As we delve into AbbVie's competitive landscape, we'll explore the company's strengths, market position, and strategic insights that have propelled it to the forefront of the pharmaceutical sector.

AbbVie's Market Position in the Pharmaceutical Industry

AbbVie has solidified its place among the top pharmaceutical companies globally, consistently ranking in the top three based on drug sales and treatments[5]. This impressive standing is a testament to the company's strategic focus and operational excellence.

Global Reach and Market Presence

With operations spanning over 70 countries and a workforce of more than 50,000 employees, AbbVie has established a truly global footprint[2]. This extensive reach allows the company to tap into diverse markets, mitigate regional risks, and capitalize on global opportunities.

Revenue Performance and Growth Trajectory

AbbVie's financial performance underscores its strong market position. In 2024, the company reported worldwide net revenues of $15.102 billion for the fourth quarter, marking a 5.6% increase on a reported basis and a 6.1% increase on an operational basis[1]. This growth trajectory is particularly impressive considering the challenges faced by the pharmaceutical industry, including patent expirations and increasing competition.

"2024 was a year of significant progress for AbbVie. Our growth platform delivered outstanding results, we advanced our pipeline with key regulatory approvals and promising data, and we strengthened our business through strategic transactions," said Robert A. Michael, chief executive officer, AbbVie[1].

AbbVie's Core Strengths and Competitive Advantages

AbbVie's success in the pharmaceutical landscape can be attributed to several key strengths that set it apart from competitors.

Robust Product Portfolio

At the heart of AbbVie's competitive advantage lies its diverse and strong product portfolio. The company has established leadership positions in key therapeutic areas, including:

1. Immunology: With blockbuster drugs like Humira, Skyrizi, and Rinvoq
2. Oncology: Featuring treatments like Imbruvica
3. Neuroscience: Bolstered by the Allergan acquisition
4. Aesthetics: A growing segment following the Allergan deal

This diversified portfolio not only provides multiple revenue streams but also helps insulate the company from the impact of patent expirations on individual products.

Research and Development Focus

AbbVie's commitment to innovation is evident in its substantial investment in research and development. The company boasts a pipeline of approximately 90 compounds[3], positioning it at the forefront of medical advancements. This focus on R&D ensures a steady stream of potential new treatments and helps maintain AbbVie's competitive edge in the long term.

Strategic Acquisitions and Partnerships

AbbVie has demonstrated a keen eye for strategic acquisitions that complement and enhance its existing portfolio. The 2020 acquisition of Allergan, for instance, significantly expanded AbbVie's presence in neuroscience and aesthetics. More recently, the company has made moves to strengthen its oncology pipeline:

• Acquisition of ImmunoGen: This $10.1 billion deal brings Elahere, a promising cancer therapy, into AbbVie's portfolio[10].
• Proposed acquisition of Cerevel Therapeutics: This move aims to bolster AbbVie's neuroscience pipeline[1].

These strategic moves not only diversify AbbVie's offerings but also position the company for future growth in key therapeutic areas.

AbbVie's Market Strategy and Future Outlook

AbbVie's market strategy is characterized by a focus on long-term growth and innovation. The company has outlined several key elements of its future outlook:

Revenue Growth Projections

AbbVie has reaffirmed its expectations for a high single-digit compound annual revenue growth rate through 2029[10]. This optimistic projection is based on the strength of its current portfolio and pipeline.

Immunology Portfolio Expansion

The company has raised its long-term outlook for Skyrizi and Rinvoq revenues. AbbVie now expects combined revenues for these two drugs to exceed $31 billion by 2027, an increase of approximately $4 billion from previous projections[1].

Aesthetics Growth

AbbVie has updated its outlook for aesthetics revenues, projecting a high single-digit compound annual revenue growth rate from 2025 through 2029[1]. This reflects the company's confidence in its aesthetics portfolio, largely gained through the Allergan acquisition.

Pipeline Advancement

AbbVie continues to invest heavily in its pipeline, with a focus on difficult-to-cure diseases[2]. The company's strategy involves both internal development and strategic acquisitions to maintain a robust pipeline of potential future treatments.

Challenges and Opportunities in the Pharmaceutical Landscape

While AbbVie's position is strong, the company faces several challenges and opportunities in the evolving pharmaceutical landscape.

Patent Expirations and Biosimilar Competition

One of the most significant challenges facing AbbVie is the loss of exclusivity for its blockbuster drug, Humira. In 2023, Humira faced biosimilar competition in the U.S., leading to a significant decline in revenues[2]. However, AbbVie has been proactive in addressing this challenge by developing new immunology treatments like Skyrizi and Rinvoq to offset the expected decline in Humira sales.

Pricing Pressures and Regulatory Changes

The pharmaceutical industry as a whole faces increasing scrutiny over drug pricing. AbbVie, like its peers, must navigate the complex landscape of pricing pressures and potential regulatory changes that could impact profitability.

Opportunities in Emerging Markets and New Therapeutic Areas

Despite these challenges, AbbVie has significant opportunities for growth. The company's global reach positions it well to capitalize on emerging markets. Additionally, AbbVie's strategic acquisitions and robust pipeline provide opportunities to expand into new therapeutic areas and solidify its position in existing ones.

Competitive Analysis: AbbVie vs. Key Rivals

To fully understand AbbVie's position in the pharmaceutical landscape, it's essential to compare it to its key competitors.

AbbVie vs. Pfizer

Pfizer, the top pharmaceutical company by revenue in 2023[2], is a formidable competitor to AbbVie. While Pfizer has a broader portfolio spanning vaccines and consumer health products, AbbVie's focused approach on specific therapeutic areas allows for deeper specialization.

AbbVie vs. Johnson & Johnson

Johnson & Johnson, which ranked second in pharmaceutical revenues in 2023[2], offers a more diversified business model that includes medical devices and consumer health products. AbbVie's pure-play pharmaceutical focus allows for more concentrated R&D efforts in its core therapeutic areas.

AbbVie vs. Merck

Merck, another top competitor, has a strong focus on oncology and vaccines. While there is some overlap in therapeutic areas, AbbVie's strength in immunology and recent expansion into aesthetics provide differentiation.

AbbVie's Innovation Pipeline and Future Treatments

AbbVie's future success heavily relies on its ability to bring new, innovative treatments to market. The company's pipeline is robust, with several promising candidates in late-stage development.

Oncology Pipeline

The acquisition of ImmunoGen has significantly bolstered AbbVie's oncology pipeline, particularly in the area of antibody-drug conjugates (ADCs). Elahere, the flagship cancer therapy from ImmunoGen, represents a significant opportunity in the treatment of platinum-resistant ovarian cancer[10].

Neuroscience Advancements

AbbVie's proposed acquisition of Cerevel Therapeutics aims to strengthen its neuroscience pipeline. This move could potentially bring new treatments for neurological and psychiatric disorders to market in the coming years[1].

Immunology Innovations

Building on the success of Skyrizi and Rinvoq, AbbVie continues to invest in new immunology treatments. The company's pipeline includes several potential new indications for these drugs, as well as novel compounds targeting various autoimmune disorders.

AbbVie's Digital Transformation and Technology Integration

In an increasingly digital world, AbbVie is leveraging technology to enhance its competitive position.

Data Analytics and Artificial Intelligence

AbbVie is investing in data analytics and artificial intelligence to accelerate drug discovery, optimize clinical trials, and improve patient outcomes. These technologies have the potential to significantly reduce the time and cost associated with bringing new treatments to market.

Digital Health Initiatives

The company is also exploring digital health solutions to complement its pharmaceutical offerings. These initiatives aim to improve patient engagement, adherence to treatment regimens, and overall health outcomes.

Environmental, Social, and Governance (ESG) Considerations

As ESG factors become increasingly important to investors and consumers, AbbVie has taken steps to address these concerns.

Sustainability Efforts

AbbVie has set ambitious environmental targets, including reducing its carbon footprint and improving water efficiency in its operations. These efforts not only contribute to global sustainability goals but also help mitigate potential regulatory and reputational risks.

Access to Medicine Initiatives

The company has implemented various programs to improve access to its medicines in underserved communities. These initiatives not only fulfill a social responsibility but also help expand AbbVie's market reach.

Key Takeaways

1. AbbVie maintains a strong market position, ranking among the top three pharmaceutical companies globally.
2. The company's diverse product portfolio, focus on R&D, and strategic acquisitions are key strengths.
3. AbbVie projects high single-digit compound annual revenue growth through 2029, driven by its immunology and aesthetics portfolios.
4. Challenges include patent expirations and pricing pressures, but opportunities exist in emerging markets and new therapeutic areas.
5. The company's robust pipeline, particularly in oncology and neuroscience, positions it well for future growth.
6. AbbVie is leveraging digital technologies and addressing ESG concerns to enhance its competitive position.

FAQs

1. Q: How is AbbVie addressing the loss of exclusivity for Humira? A: AbbVie is focusing on the growth of newer immunology drugs like Skyrizi and Rinvoq, which are expected to offset the decline in Humira sales. The company has also diversified its portfolio through strategic acquisitions.

2. Q: What are AbbVie's key therapeutic areas? A: AbbVie's key therapeutic areas include immunology, oncology, neuroscience, and aesthetics.

3. Q: How does AbbVie's R&D investment compare to industry peers? A: AbbVie maintains a strong focus on R&D, with a pipeline of approximately 90 compounds. While specific investment figures vary, this commitment to innovation is on par with or exceeds many industry peers.

4. Q: What recent acquisitions has AbbVie made to strengthen its position? A: Recent notable acquisitions include ImmunoGen to bolster its oncology portfolio and the proposed acquisition of Cerevel Therapeutics to enhance its neuroscience pipeline.

5. Q: How is AbbVie incorporating digital technologies into its business model? A: AbbVie is leveraging data analytics and artificial intelligence for drug discovery and development. The company is also exploring digital health solutions to improve patient outcomes and engagement.

Sources cited: [1] https://www.prnewswire.com/news-releases/abbvie-reports-full-year-and-fourth-quarter-2024-financial-results-302364968.html [2] https://www.proclinical.com/blogs/2024-7/who-are-the-top-10-pharma-companies-in-the-world-2024 [3] https://www.gurufocus.com/news/2496601/decoding-abbvie-inc-abbv-a-strategic-swot-insight [5] https://www.statista.com/topics/9191/abbvie/ [10] https://investors.abbvie.com/news-releases/news-release-details/abbvie-reports-full-year-and-fourth-quarter-2023-financial